Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Collegium Pharma (COLL) Misses Q4 EPS by 9c
February 25, 2021 5:18 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.20, $0.09 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $76.3 million versus the consensus estimate of $77.41 million.
Our differentiated pain portfolio performed well during the fourth quarter, laying the groundwork for a strong start in the new year, said... More
